Evidence map›Paper›PMID 38165530›Full record

ArticleDrug delivery and translational research2024

The selection of animal models influences the assessment of anti-tumor efficacy: promising sialic acid-conjugate modified liposomes demonstrate remarkable therapeutic effects in diverse mouse strains.

Lu Wei, Lin Lin, Jia Wang, Xinying Guan, Wen Li, Yangxu Gui, Shupei Liao, Mingyang Wang, Jiaqi Li, Yihui Deng and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Lu WeiCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Lin LinCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Jia WangCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Xinying GuanCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Wen LiCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Yangxu GuiCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Shupei LiaoCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Mingyang WangCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Jiaqi LiCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Yihui DengCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China.
Yanzhi SongCollege of Pharmacy, Shenyang Pharmaceutical University, 110016, Shenyang, China. songyanzhi@syphu.edu.cn.ORCID 0000-0002-8504-7443
Shenyang Pharmaceutical University · CN

Funding

Career Development Support Plan for Young and Middle-aged Teachers at the Shenyang Pharmaceutical University ZDN2021009
6 · The paper itself

Abstract

Mice as a crucial tool for preclinical assessment of antineoplastic agents. The impact of physiological differences among mouse strains on the in vivo efficacy of antitumor drugs, however, has been significantly overlooked. Mononuclear phagocyte system (MPS) is the major player in clearance in vivo, and differences in MPS among different strains may potentially impact the effectiveness of antitumor preparations. Therefore, in this study, we employed conventional liposomes (CL-EPI) and SA-ODA modified liposomes (SAL-EPI) as model preparations to investigate the comprehensive tumor therapeutic effects of CL-EPI and SAL-EPI in KM, BALB/c, and C57BL/6 tumor-bearing mice. The results demonstrated significant variability in the efficacy of CL-EPI for tumor treatment across different mouse strains. Therefore, we should pay attention to the selection of animal models in the study of antitumor agents. SAL-EPI effectively targeted tumor sites by binding to Siglec-1 on the surface of peripheral blood monocytes (PBMs), and achieved good therapeutic effect in different mouse strains with little difference in treatment. The SA modified preparation is therefore expected to achieve a favorable therapeutic effect in tumor patients with different immune states through PBMs delivery (Siglec-1 was expressed in both mice and humans), thereby possessing clinical translational value and promising development prospects.

Indexed as

Antineoplastic AgentsLiposomesMice, Inbred BALB CMice, Inbred C57BLAnimalsCell Line, TumorDisease Models, AnimalFemaleMiceN-Acetylneuraminic AcidSialic Acid Binding Ig-like Lectin 1Species SpecificityAntineoplastic AgentsLiposomesN-Acetylneuraminic AcidSialic Acid Binding Ig-like Lectin 1Siglec1 protein, mouseAnimal modelDifferent mouse strainsPeripheral blood monocytesSialic acid modified liposomesTumor

Identifiers

PMID38165530
OpenAlexW4390508271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.